Cord Blood News Volume 4.25 | Jun 28 2012

    0
    113

    Cord Blood News 4.25 June 28, 2012

         In this issue: Publications | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Cord Blood News on Twitter

    TOP STORY
    Human Umbilical Cord Mesenchymal Stem Cells Support Non-Tumorigenic Expansion of Human Embryonic Stem Cells
    Researchers tested human umbilical cord-derived mesenchymal stem cells as the feeder for human embryonic stem cells. [Cell Transplant] Abstract

    Technical Bulletin: Assays For Cord Blood

    PUBLICATIONS (Ranked by impact factor of the journal)

    Isolation and Characterization of Canine Wharton’s Jelly-Derived Mesenchymal Stem Cells
    The authors successfully isolated and characterized mesenchymal stem cells from canine Wharton’s jelly. [Cell Transplant] Abstract

    Expression and Inducibility of Cytochrome P450s in Human Cord Blood CD34+ Stem Cell Derived Differentiating Neuronal Cells
    The status of xenobiotic metabolism in developing human brain cells is not known. The reason being is non-availability of developing human fetal brain. Researchers investigated the applicability of plasticity potential of human umbilical cord blood stem cells for the purpose. [Toxicol Sci] Abstract

    Human Endothelial Progenitor Cells Induce Extracellular Signal-Regulated Kinase-Dependent Differentiation of Mesenchymal Stem Cells into Smooth-Muscle Cells Upon Cocultivation
    Endothelial progenitor cells (EPCs) from two different origins, namely adult peripheral blood and neonatal cord blood, or human umbilical vein endothelial cells were cocultured with human mesenchymal stem cells (MSCs) to analyze the effect on MSC differentiation towards a smooth muscle cell/pericyte phenotype. [Tissue Eng Part A] Abstract

    Human Umbilical Cord Perivascular Cells Improve Rat Hepatocyte Function Ex Vivo
    Researchers concluded that human umbilical cord perivascular cells can act as stromal cells for rat hepatocytes, and that soluble and non-soluble factors induce differential effects on hepatocytes. [Tissue Eng Part A] Abstract

    Human Umbilical Cord Blood-Derived CD34+ Cells Reverse Osteoporosis in NOD/SCID Mice by Altering Osteoblastic and Osteoclastic Activities
    Researchers showed that CD34+ cells could be differentiated into osteoblastic lineage in vitro. Systemically delivered CD34+ cells homed to the bone marrow and significantly improved bone deposition, bone mineral density and bone micro-architecture in osteoporotic mice. [PLoS One] Full Article

    A Potential Role for B Cells in Suppressed Immune Responses in Cord Blood Transplant Recipients
    Investigators evaluated immune reconstitution in 58 adults who received hematopoietic SCTs from allogeneic siblings, matched unrelated donors or cord blood at 90-day intervals for one year post transplant. [Bone Marrow Transplant] Abstract

    Association of CFU-Mk with Total Colony-Forming Units in Thawed Cord Blood Units
    Megakaryocytic colony-forming unit (CFU-Mk) growth was associated with total CFU, hemoglobinized CFU, CFU-granulocyte/macrophage and CD34+ cells in thawed cord blood (CB) units. This study confirms the preservation of CFU-Mk potential after CB cryopreservation. [Vox Sang] Abstract

    Stemness Gene Expression Profile Analysis in Human Umbilical Cord Mesenchymal Stem Cells
    Scientists investigated the normal mRNA expression profile of umbilical cord mesenchymal stem cells (UC-MSCs), and analyzed the candidate proteins responsible for the signaling pathway that may affect the differentiation characteristics of UC-MSCs. [Exp Biol Med] Abstract

    Improve Quality Control and Regulatory Compliance. Watch the video to see how StemLab can help.

    INDUSTRY NEWS

    HemoGenix® FDA Master File to Measure Blood Stem Cell Potency for Cellular Therapy Products: Advanced Tests for Umbilical Cord Blood Stem Cell Transplantation to Help Reduce Engraftment Failure
    HemoGenix® announced that FDA CBER has given HemoGenix® its first Master File Number for an in vitro blood stem cell potency, quality and release assay for cellular therapy products used for stem cell transplantation purposes. [HemoGenix, Inc] Press Release

    BioCells (Argentina) and Cord Blood America, Inc. Reach Agreement on Payments
    Cord Blood America, Inc. (CBAI) is pleased to announce it has finalized an Agreement with the individuals from whom CBAI acquired its majority interest in BioCordcell Argentina, S.A. regarding the 2011 earn-out. [PR Newswire] Press Release

    New Scottish-Californian Stem Cell Research Announced
    Scientists from Heriot-Watt together with their counterparts in St Andrews and Stanford universities are to work together on new medical research that could lead to major breakthroughs for people living with life-threatening conditions. The Heriot-Watt and St Andrews teams will work with research groups at Stanford to examine how stem cells grow and divide and how they change shape to form different types of tissue. [Heriot-Watt University] Press Release

    Connexon Creative - Complete our survey and be entered in a draw to win one of 50 Starbucks gift cards!
    We care what you think! Please help Connexon Creative improve our newsletters by taking our survey. For responding, you will be entered in a draw to win one of 50 Starbucks gift cards valued at $10 each!* Enter here
    *Starbucks promotion only applies where Starbucks gift cards are redeemable. Prizes will be given at random when survey closes.

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS
    NEW 2nd International Placenta Stem Cell Society (IPLASS) Meeting: The Regenerative Potential of Placenta-Derived Cells
    September 5, 2012
    Vienna, Austria


    Visit
    our events page to see a complete list of events in the cord blood community.

    JOB OPPORTUNITIES

    Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

    Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

    Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

    Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

    Research Associate – Chemistry (STEMCELL Technologies, Inc.)

    Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

    Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

    Research Technologist – Media Development (STEMCELL Technologies, Inc.)

    Business Development Manager – Stem Cell (SynGen Inc.)

    Controller (SynGen Inc.)

    Director: Regulatory Affairs (SynGen Inc.)

    Manufacturing Manager (SynGen Inc.)

    Chief Scientific Officer (SynGen Inc.)

    Group Leaders, Principle Scientists – Stem Cell Clinical Product R&D (Shanghai Hengrui Pharmaceuticals Co., Ltd)

    Stem Cell Therapy Scientist (Paramount Recruitment)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Have we missed an important article or publication in Cord Blood News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Cord Blood News: Archives | Events | Contact Us